European Respiratory Journal

The European Respiratory Journal (ERJ), which had an impact factor of 8.332 in 2015, is the official publication of the European Respiratory Society (ERS). This journal covers a wide range of topics related to respiratory medicine. It features both clinical and experimental research in areas such as lung cell biology, epidemiology, immunology, pathophysiology, thoracic imaging, pediatric pulmonology, occupational health, intensive care, sleep medicine, and thoracic surgery and oncology.

Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Epigenetic Aging: Leveraging DNA Methylation in Chronic Respiratory Diseases

Oct 3, 2024 | erj.ersjournals.com | Janice M. Leung

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: J.
Optimisation of detecting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism survivors: the InShape IV study

Oct 3, 2024 | erj.ersjournals.com | Luca Valerio |Stefano Barco |Harm Jan Bogaard |Marion Delcroix

FootnotesConflict of interest: S. Barco received research support from Boston Scientific, Medtronic, Concept Medical, Sanofi and Novartis, all outside this manuscript. M. Delcroix received consulting fees from Actelion/Janssen/J&J, Acceleron/MSD, Gossamer and Ferrer; and payment or honoraria for lectures, presentations, manuscript writing or educational events from Actelion/Janssen/J&J, Acceleron/MSD and Ferrer, all outside the submitted work. L.
What to do when pulmonary arterial hypertension screening suggests neither fish nor fowl? The DOLPHIN-GENESIS study

Oct 3, 2024 | erj.ersjournals.com | Mark Toshner

FootnotesConflict of interest: M. Toshner declares relationships with Janssen Pharmaceuticals Inc., Merck Sharp & Dohme UK Ltd, and Apollo Therapeutics that include consulting and/or advisory work. E.M.D.D. De Bie has no potential conflicts of interest to disclose. Support statement: M. Toshner is supported by the NIHR Cambridge Biomedical Research Centre. E.M.D.D. De Bie is supported by the Gates Cambridge Trust (Gates grant number OPP1144).
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

Sep 26, 2024 | erj.ersjournals.com | Michael E. Wechsler |Guy G. Brusselle |J. Christian Virchow |Stephanie Roseti

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: A. Versi has nothing to disclose.
Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor

Sep 26, 2024 | erj.ersjournals.com | Peter Middleton |Nicholas Simmonds

Footnotes Conflict of interest: P.G. Middleton reports grants from HCF Australia and the Canadian Institutes of Health, consultancy fees from Vertex Pharma, payment or honoraria for lectures, presentations, manuscript writing or educational events from Vertex Pharma, AstraZeneca and Limbic, payment for expert testimony from Shine Lawyers, support for attending meetings from NSW Health, participation on a data safety monitoring board or advisory board with Cystic Fibrosis Foundation, is a...
Reply: Guideline recommendations don't exist in a vacuum

Sep 26, 2024 | erj.ersjournals.com | Steven Walker |Rob Hallifax |Nick A. Maskell

Reply to I.S. Tournoy and K.G. Tournoy:The letter “Debunking the myth: why wall suction should not be routine in pneumothorax treatment” postulated that negative pressure via thoracic suction may lead to worse outcomes for patients and suggests that the joint ERS/EACTS/ESTS clinical practice guidelines on adults with spontaneous pneumothorax [1] should be amended. This hypothesis may be correct. It could also be wrong.
CD94+ natural killer cells potentiate pulmonary ischaemia-reperfusion injury

Sep 26, 2024 | erj.ersjournals.com | Alberto Hernandez |Alberto Hernández |Simon Cleary |Nancy Y. Greenland |Jesse Santos

FootnotesEthics statement: Our study was conducted under approved protocols from our animal and human research committees. Written informed consent was obtained from all participants prior to inclusion in the study. All animal procedures and experiments were conducted according to protocols approved by the UCSF Institutional Animal Care Use Committee. Author contributions: Conceptualisation: D.R. Calabrese, L.L. Lanier, J.R. Greenland, R. Shi, J. Richardson. Methodology: D.R. Calabrese, T. Tsao, L.
10 pack-years of smoking: not the magic number for COPD risk and prognosis

Sep 12, 2024 | erj.ersjournals.com | Helena Backman

Threshold values play a critical role in clinical medicine, as they provide standardised criteria for diagnosis and treatment, ensuring consistency across different healthcare providers and settings. They help in maintaining uniformity in patient care, making sure that patients with similar characteristics receive similar evaluations and interventions.
Allergen challenge, eosinophils and the long road to asthma endotypes

Sep 12, 2024 | erj.ersjournals.com | Sally Wenzel |Pa Usa

FootnotesConflict of interest: S.E. Wenzel reports grants and consultancy fees from Regeneron, and stock (or stock options) in Aer Therapeutics. Received July 8, 2024. Accepted July 8, 2024. View Full Text ERS Members myERS - ERS members : log in with your myERS username and password. INDIVIDUALS Login as an individual user. Forgot your username or password?
Taking your mind off breathlessness

Sep 12, 2024 | erj.ersjournals.com | Peter M.A. Calverley

FootnotesConflict of interest: P.M.A. Calverley reports receiving grants, personal fees and non-financial support from pharmaceutical companies that make medicines to treat respiratory disease. This includes reimbursement for educational activities and advisory work, and support to attend meetings. Received June 13, 2024. Accepted June 13, 2024. View Full Text ERS Members myERS - ERS members : log in with your myERS username and password.